We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Do you have psoriasis? Have you been treated with either COSENTYX® (secukinumab) or Taltz® (ixekizumab) for the past 6 months but still have symptoms of psoriasis? You may be able to participate in a study to test how safe and effective the drug SKYRIZI™ (risankizumab) is in treating psoriasis. Participation in this study will last up to 64 weeks. Compensation & travel reimbursement provided.
IRB: SSU00144685
- AbbVie - US - M19-164, A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to risankizumab. (Pro00037820)MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.